Caribou Biosciences (CRBU) Stock Forecast & Price Target

Compare

766 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRBU Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Caribou

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRBU Stock 12 Month Forecast

Average Price Target

$5.20

▲(128.07%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Caribou Biosciences in the last 3 months. The average price target is $5.20 with a high forecast of $10.00 and a low forecast of $1.00. The average price target represents a 128.07% change from the last price of $2.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.9230769230769231,2.5961538461538463,3.269230769230769,3.9423076923076925,4.615384615384616,5.288461538461538,5.961538461538462,6.634615384615385,7.307692307692308,7.980769230769232,8.653846153846153,9.326923076923077,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.5538461538461539,1.8576923076923078,2.161538461538462,2.4653846153846155,2.769230769230769,3.0730769230769233,3.3769230769230774,3.680769230769231,3.9846153846153847,4.288461538461538,4.592307692307693,4.8961538461538465,{"y":5.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.25,1.2307692307692308,1.2115384615384615,1.1923076923076923,1.1730769230769231,1.1538461538461537,1.1346153846153846,1.1153846153846154,1.0961538461538463,1.0769230769230769,1.0576923076923077,1.0384615384615383,1.0192307692307692,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.05,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$5.20

Lowest Price Target$1.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$2.5

Hold

9.65%

Upside

Reiterated

07/23/25

Caribou Biosciences faces significant challenges due to declining revenues and ongoing losses, impacting its financial score. Despite positive technical indicators suggesting bullish momentum, the stock is overbought, posing risks of a correction. Valuation challenges persist due to negative earnings, though maintaining Nasdaq compliance supports investor confidence.

Alec StranahanBank of America Securities

Bank of America Securities

Buy

294.74%

Upside

Reiterated

05/14/25

Bank of America Securities Reaffirms Their Buy Rating on Caribou Biosciences (CRBU)

Liisa BaykoEvercore ISI

Evercore ISI

$3→$1

Hold

-56.14%

Downside

Reiterated

05/12/25

Caribou Biosciences (CRBU) Receives a Hold from Evercore ISI

Mani ForooharLeerink Partners

Leerink Partners

Buy

31.58%

Upside

Reiterated

05/09/25

Caribou Biosciences: Strong Pipeline and Financial Position Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$11→$10

Buy

338.60%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH), Caribou Biosciences (NASDAQ: CRBU) and Cidara Therapeutics (NASDAQ: CDTX)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$9→$3

Buy

31.58%

Upside

Reiterated

04/28/25

Strategic Refocus and Upcoming Catalysts Support Buy Rating for Caribou Biosciences

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

03/20/25

Truist Financial Remains a Buy on Caribou Biosciences (CRBU)

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

$26→$34

Buy

1391.23%

Upside

Reiterated

01/06/25

Caribou Biosciences price target raised to $34 from $26 at BrooklineCaribou Biosciences price target raised to $34 from $26 at Brookline

Yigal NochomovitzCiti

Citi

$30→$6

Buy

163.16%

Upside

Reiterated

11/26/24

Caribou Biosciences price target lowered to $6 from $30 at CitiCaribou Biosciences price target lowered to $6 from $30 at Citi

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$2.5

Hold

9.65%

Upside

Reiterated

07/23/25

Alec StranahanBank of America Securities

Bank of America Securities

Buy

294.74%

Upside

Reiterated

05/14/25

Bank of America Securities Reaffirms Their Buy Rating on Caribou Biosciences (CRBU)

Liisa BaykoEvercore ISI

Evercore ISI

$3→$1

Hold

-56.14%

Downside

Reiterated

05/12/25

Caribou Biosciences (CRBU) Receives a Hold from Evercore ISI

Mani ForooharLeerink Partners

Leerink Partners

Buy

31.58%

Upside

Reiterated

05/09/25

Caribou Biosciences: Strong Pipeline and Financial Position Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$11→$10

Buy

338.60%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (NASDAQ: AVAH), Caribou Biosciences (NASDAQ: CRBU) and Cidara Therapeutics (NASDAQ: CDTX)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$9→$3

Buy

31.58%

Upside

Reiterated

04/28/25

Strategic Refocus and Upcoming Catalysts Support Buy Rating for Caribou Biosciences

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

03/20/25

Truist Financial Remains a Buy on Caribou Biosciences (CRBU)

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

$26→$34

Buy

1391.23%

Upside

Reiterated

01/06/25

Caribou Biosciences price target raised to $34 from $26 at BrooklineCaribou Biosciences price target raised to $34 from $26 at Brookline

Yigal NochomovitzCiti

Citi

$30→$6

Buy

163.16%

Upside

Reiterated

11/26/24

Caribou Biosciences price target lowered to $6 from $30 at CitiCaribou Biosciences price target lowered to $6 from $30 at Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Caribou Biosciences

1 Month

xxx

Success Rate

6/17 ratings generated profit

Average Return

+1.61%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 35.29% of your transactions generating a profit, with an average return of +1.61% per trade.

3 Months

xxx

Success Rate

9/20 ratings generated profit

Average Return

+12.57%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of +12.57% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

6/20 ratings generated profit

Average Return

-13.43%

reiterated a buy rating 3 months ago

Copying Robert Burns's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -13.43% per trade.

2 Years

xxx

Success Rate

6/20 ratings generated profit

Average Return

-18.60%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 30.00% of your transactions generating a profit, with an average return of -18.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRBU Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRBU has received 4 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. CRBU average Analyst price target in the past 3 months is 5.20.

Each month's total comprises the sum of three months' worth of ratings.

CRBU Financial Forecast

CRBU Earnings Forecast

Next quarter’s earnings estimate for CRBU is -$0.39 with a range of -$0.42 to -$0.35. The previous quarter’s EPS was -$0.43. CRBU beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.96% of the time in the same period. In the last calendar year CRBU has Preformed in-line its overall industry.

CRBU Sales Forecast

Next quarter’s sales forecast for CRBU is $1.89M with a range of $0.00 to $2.50M. The previous quarter’s sales results were $2.35M. CRBU beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year CRBU has Preformed in-line its overall industry.

CRBU Stock Forecast FAQ

What is CRBU’s average 12-month price target, according to analysts?

Based on analyst ratings, Caribou Biosciences’s 12-month average price target is 5.20.

What is CRBU’s upside potential, based on the analysts’ average price target?

Caribou Biosciences has 128.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRBU a Buy, Sell or Hold?

Caribou Biosciences has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Caribou Biosciences’s price target?

The average price target for Caribou Biosciences is 5.20. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 128.07% Increase from the current price of $2.28.

What do analysts say about Caribou Biosciences?

Caribou Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of CRBU?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Caribou Biosciences (CRBU) Stock Forecast & Price Target

CRBU Analyst Ratings

CRBU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Caribou Biosciences

CRBU Analyst Recommendation Trends

CRBU Financial Forecast

CRBU Earnings Forecast

CRBU Sales Forecast

CRBU Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts